Seegene, a biotechnology firm based in Seoul that specializes in molecular diagnostics (MDx), is unveiling a fully automated PCR testing system this week at the 2021 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo in Atlanta.
The STARlet-AIOS is Seegene’s first fully automated molecular testing system. Short for “all in one system,” the AIOS provides high-throughput, real-time PCR workflow, from nucleic acid extraction to real-time PCR to result interpretation. AIOS is designed in a modular concept, which compiles Seegene’s high multiplex, real-time PCR technologies.
This MDx system is composed of independent and detachable modules together with its proprietary software architecture. AIOS is designed with an extraction/liquid handler and PCR instrument, integrated with an in-house developed robotic arm module. Hospitals and laboratories can either purchase the full AIOS package or integrate their existing instruments on site, if they already have Seegene’s liquid handler and real-time PCR instrument.
The high-throughput automated syndromic MDx system also adopts a variety of Seegene’s currently available assays, which allows for symptom-based tests. The system can identify the exact cause of a specific symptom with a single tube, to help enable both cost- and time-effective tests. According to the company, the modular and assay features will make AIOS affordable to small- to medium-sized hospitals.
“AIOS represents Seegene’s decades-long commitment to developing cutting-edge technologies in the molecular diagnostics field,” says Jong-Yoon Chun, PhD, CEO of Seegene. “I believe AIOS will contribute to the public health by making MDx more accessible in everyday life.”
For more information, visit Seegene.
Featured Image: Seegene’s first fully automated MDx system, the STARlet-AIOS, integrates the company’s liquid handler and real-time PCR instruments. Photo: Seegene
